Point72 Asset Management L.P. boosted its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 16.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,856,750 shares of the company's stock after buying an additional 256,010 shares during the period. Point72 Asset Management L.P. owned approximately 3.28% of Design Therapeutics worth $11,456,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of DSGN. Invesco Ltd. bought a new position in shares of Design Therapeutics during the fourth quarter valued at approximately $71,000. ProShare Advisors LLC bought a new position in Design Therapeutics in the 4th quarter valued at $71,000. China Universal Asset Management Co. Ltd. purchased a new stake in Design Therapeutics in the fourth quarter worth $74,000. Kennedy Capital Management LLC bought a new stake in shares of Design Therapeutics during the fourth quarter worth $88,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Design Therapeutics during the fourth quarter valued at $109,000. 56.64% of the stock is currently owned by institutional investors.
Design Therapeutics Price Performance
DSGN stock opened at $3.51 on Monday. Design Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $7.77. The firm's 50-day moving average is $3.88 and its 200 day moving average is $4.88. The company has a market capitalization of $199.26 million, a PE ratio of -4.13 and a beta of 1.77.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). Sell-side analysts forecast that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.
About Design Therapeutics
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
